Jade Biosciences (NASDAQ:JBIO) Sees Unusually-High Trading Volume Following Analyst Upgrade

Jade Biosciences, Inc. (NASDAQ:JBIO) shares saw an uptick in trading volume on Tuesday after William Blair upgraded the stock to a strong-buy rating. 685,419 shares were traded during trading, an increase of 154% from the previous session’s volume of 269,583 shares.The stock last traded at $15.0520 and had previously closed at $14.43.

Several other brokerages have also issued reports on JBIO. Lifesci Capital upgraded shares of Jade Biosciences to a “strong-buy” rating in a research note on Friday. Stifel Nicolaus set a $40.00 price target on shares of Jade Biosciences in a report on Friday. HC Wainwright assumed coverage on shares of Jade Biosciences in a research report on Wednesday, January 7th. They issued a “buy” rating and a $25.00 target price for the company. Wedbush reissued an “outperform” rating and set a $24.00 price target on shares of Jade Biosciences in a research note on Monday. Finally, Guggenheim raised their price target on Jade Biosciences from $14.00 to $17.00 and gave the stock a “buy” rating in a research report on Tuesday, November 18th. Two research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $25.00.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. RA Capital Management L.P. increased its stake in Jade Biosciences by 245.6% in the 4th quarter. RA Capital Management L.P. now owns 3,671,083 shares of the company’s stock worth $56,645,000 after buying an additional 2,608,757 shares in the last quarter. Frazier Life Sciences Management L.P. purchased a new stake in shares of Jade Biosciences during the 2nd quarter valued at about $17,703,000. Baker BROS. Advisors LP purchased a new position in shares of Jade Biosciences in the 4th quarter worth approximately $25,323,000. Remedium Capital Partners LLC bought a new position in Jade Biosciences during the fourth quarter valued at $24,345,000. Finally, Versant Venture Management LLC purchased a new position in shares of Jade Biosciences during the second quarter valued at approximately $15,243,000.

Jade Biosciences Price Performance

The firm has a 50-day moving average price of $14.75 and a two-hundred day moving average price of $12.00. The firm has a market capitalization of $737.68 million, a P/E ratio of -3.26 and a beta of 1.03.

Jade Biosciences (NASDAQ:JBIO) last announced its quarterly earnings results on Friday, March 6th. The company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.45) by $0.34.

About Jade Biosciences

Jade Biosciences, Inc is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics for inflammatory skin diseases and chronic itch. Leveraging a small‐molecule platform, the company seeks to address significant unmet needs in dermatology by targeting key pathways involved in pruritus and skin inflammation. Its research efforts are centered on identifying and advancing molecules that can modulate receptor activity in the skin, with a goal of improving safety and efficacy compared to existing treatments.

The company’s lead programs are built around proprietary compounds designed to penetrate the epidermal barrier and selectively inhibit molecular drivers of itch and inflammation.